<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02877628</url>
  </required_header>
  <id_info>
    <org_study_id>35RC13_8962_OPTILTH</org_study_id>
    <nct_id>NCT02877628</nct_id>
  </id_info>
  <brief_title>Immunosuppressive Therapy Optimization: Development of a Population Pharmacokinetic-pharmacodynamic (PK-PD) Model in Liver Transplantation</brief_title>
  <acronym>OPTILTH</acronym>
  <official_title>Immunosuppressive Therapy Optimization: Development of a Population Pharmacokinetic-pharmacodynamic (PK-PD) Model in Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, non-randomized, open Pharmacokinetic-Pharmacogenetic-Pharmacodynamic monocentric
      study. Donor and recipient CYP3A5 genotype and recipient ABCB1 will not be communicate to
      clinicians or patients during the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prediction of calcineurin inhibition, responsible for the immunosuppressive effect</measure>
    <time_frame>Week 24</time_frame>
    <description>Assessement of the relationships between tacrolimus dosage, whole-blood and intracellular concentrations</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prediction of calcineurin inhibition, responsible for the immunosuppressive effect</measure>
    <time_frame>Week 24</time_frame>
    <description>Assessement of the relationships between intracellular concentrations of tacrolimus and calcineurin activity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prediction of calcineurin inhibition, responsible for the immunosuppressive effect</measure>
    <time_frame>Week 24</time_frame>
    <description>Assessement of the relationships between donor and recipient CYP3A5 and ABCB1 genotypes and dose/concentration of tacrolimus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Prediction of calcineurin inhibition, responsible for the immunosuppressive effect</measure>
    <time_frame>Week 24</time_frame>
    <description>Assessement of the relationships between intracellular concentration of tacrolimus and/or calcineurin activity and ACR, in patients treated with immediate release or modified-release formulation of tacrolimus</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Study of impact of pharmacogenetic and demographic data on tacrolimus intracellular concentration</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the role of the measurement of intracellular concentration as a longitudinal biomarker in preventing acute cellular graft (ACR)</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study of variability of tacrolimus intracellular concentration according to its pharmaceutic form (immediate or sustained release)</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Liver Transplantation</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacokinetic-pharmacodynamic model in liver transplantation</intervention_name>
    <description>Biological: tacrolimus and calcineurin dosage, donor and recipient CYP3A5 and ABCB1 genotypes determination</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with liver tranplantation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults over 18

          -  Liver transplant recipients

          -  Treated with an immunosuppressive protocol with tacrolimus

          -  Informed on the study and who did not refuse to participate

        Exclusion Criteria:

          -  Patients who participate in a study with procedures incompatible with the present
             study.

          -  Patients with legal protection/deprived of liberty.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eric Bellissant, MD, PhD</last_name>
    <phone>3 2 99 28 37 15</phone>
    <email>eric.bellissant@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Florian Lemaitre, PhD</last_name>
    <phone>2 99 28 67 55</phone>
    <email>florian.lemaitre@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florian Lemaitre, PhD</last_name>
      <phone>33 2 28 67 55</phone>
      <email>florian.lemaitre@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Bellissant, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karim Boudjema, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel Rayar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe Camus, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique David, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pauline Houssel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Marie Jouanolle, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caroline Jezequel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mickaël Roussel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Clémence Verdier, Pharm D, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benoit Blanchet, Pharm D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Camille Tron</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>August 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2016</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetic</keyword>
  <keyword>pharmacodynamic</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>CYP3A5</keyword>
  <keyword>liver transplantation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Extracts</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

